Diversify Advisory Services LLC Has $2.86 Million Position in Tempus AI, Inc. $TEM

Key Points

• Diversify Advisory Services LLC cut its stake in Tempus AI by 50.7% in Q4, leaving 48,413 shares valued at approximately $2.86 million.
• Insider selling has been heavy: insiders sold 563,841 shares worth about $32.26 million over the past 90 days, and insiders now own 26.27% of the stock.
• Analyst sentiment is mixed-to-positive — the consensus is a Moderate Buy with an average target of $75.92 — while the stock remains volatile (beta 4.90) and is trading below its 200‑day SMA (50‑day $51.10 vs 200‑day $66.86).

Diversify Advisory Services LLC reduced its stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 50.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,413 shares of the company's stock after selling 49,693 shares during the quarter. Diversify Advisory Services LLC's holdings in Tempus AI were worth $2,859,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the third quarter worth approximately $28,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Tempus AI during the third quarter worth approximately $38,000. Finally, Lodestone Wealth Management LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth approximately $42,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $42.94 on Friday. The firm has a 50 day simple moving average of $51.10 and a 200 day simple moving average of $66.86. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm has a market cap of $7.68 billion, a P/E ratio of -30.45 and a beta of 4.90. Tempus AI, Inc. has a fifty-two week low of $38.79 and a fifty-two week high of $104.32.

Insider Transactions at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 2,902 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $171,363.10. Following the completion of the sale, the chief accounting officer directly owned 41,159 shares in the company, valued at $2,430,438.95. This trade represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James William Rogers sold 10,084 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the sale, the chief financial officer owned 101,166 shares of the company's stock, valued at approximately $5,973,852.30. The trade was a 9.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 563,841 shares of company stock valued at $32,258,311. 26.27% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Mizuho assumed coverage on Tempus AI in a research note on Thursday, February 19th. They issued an "outperform" rating and a $100.00 target price for the company. Guggenheim lowered their target price on Tempus AI from $95.00 to $60.00 and set a "buy" rating for the company in a research note on Monday, March 30th. Wall Street Zen lowered Tempus AI from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They issued an "outperform" rating and a $59.00 target price for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a report on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $75.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.